Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

OTHER 1

Study Type

Interventional 22Observational 12Expanded_access 1

Sponsor

Cancer Type

Sarcoma 4Thoracic 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Leukemia 10Myelodysplastic Syndromes 6Leukemia, Lymphocytic, Chronic, B-Cell 6Recurrence 5Lymphoma 5Hematologic Neoplasms 5Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Immunologic Deficiency Syndromes 3Blast Crisis 3Waldenstrom Macroglobulinemia 2Precancerous Conditions 2Neoplasms 2Multiple Myeloma 2Mastocytosis, Systemic 2Leukemia, Promyelocytic, Acute 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Mast-Cell 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Diseases 2Graft vs Host Disease 2Congenital Abnormalities 2Burkitt Lymphoma 2Bone Marrow Failure Disorders 2Thalassemia 1Syndrome 1

Interventions

glucarpidase 1Carboxypeptidases 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Osteosarcoma × Other hematologic neoplasm × Clear all
NCT00481559 2014-01-17

Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity

BTG International Inc.

Approved for marketing
LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neoplasms, Osteosarcoma, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡